# Massimo Cristofanilli

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/massimo-cristofanilli/

## Facts

| Field | Value |
| --- | --- |
| Citations | 58,581 |
| Field | Cancer Cells and Metastasis |
| h-index | 112 |
| i10-index | 435 |
| Last Known Institution | NewYork–Presbyterian Brooklyn Methodist Hospital |
| OpenAlex ID | https://openalex.org/A5032987754 |
| ORCID iD | https://orcid.org/0000-0002-4194-7175 |
| Works | 1,443 |

## Researcher papers

- [Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer](https://scholariq.org/papers/response-to-neoadjuvant-therapy-and-long-term-survival-in-patients-with-triple/)
- [Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by <i>HER2</i> Immunophenotype and Gene Amplification](https://scholariq.org/papers/weekly-trastuzumab-and-paclitaxel-therapy-for-metastatic-breast-cancer-with/)
- [International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment](https://scholariq.org/papers/international-expert-panel-on-inflammatory-breast-cancer-consensus-statement-for/)
- [Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes](https://scholariq.org/papers/invasive-lobular-carcinoma-classic-type-response-to-primary-chemotherapy-and/)
- [Inflammatory Breast Cancer: The Disease, the Biology, the Treatment](https://scholariq.org/papers/inflammatory-breast-cancer-the-disease-the-biology-the-treatment/)
- [Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer](https://scholariq.org/papers/response-to-neoadjuvant-therapy-and-long-term-survival-in-patients-with-triple-2/)
- [ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer](https://scholariq.org/papers/icam1-initiates-ctc-cluster-formation-and-trans-endothelial-migration-in-lung/)
- [Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/tucidinostat-plus-exemestane-for-postmenopausal-patients-with-advanced-hormone/)
- [Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)](https://scholariq.org/papers/challenges-and-opportunities-of-cfdna-analysis-implementation-in-clinical/)

## Researcher topics

- [Cancer Cells and Metastasis](https://scholariq.org/topics/cancer-cells-and-metastasis/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Research and Treatments](https://scholariq.org/topics/cancer-research-and-treatments/)

## Researcher university

- [NewYork–Presbyterian Brooklyn Methodist Hospital](https://scholariq.org/institutions/newyork-presbyterian-brooklyn-methodist-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.